FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Articles
A “Rock Star” in Patient-Reported Outcomes, Is Listening
Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.
Osimertinib With or Without Chemo is Top Choice for Frontline NSCLC
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
About
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective,…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies
Key PointsAfter 6 weeks of treatment, response was achieved in 24 of 28 patients (85.7%).Thrombotic events were reported for 3 patients (10.7%), none of wh
December II, 2024
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
ANNUAL REVIEW ISSUE: HAEMATOLYMPHOID MALIGNANCIES: BEYOND THE CURRENT CLASSIFICATIONS: Histopathology: Vol 86, No 1
Click on the title to browse this issue
Advancing the Future of Diagnostics and Regulatory Innovations – Friends of Cancer Research
Advancing the Future of Diagnostics and Regulatory Innovations Tuesday, February 4, 2025 10AM – 2PM ET The Ritz Carlton 1150 22nd St NW, Washington, DC…
A Look at Poor Outcomes in Triple-Class Exposed Multiple… : Oncology Times
An abstract is unavailable.
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
